Alnylam presents additional results from the apollo-b phase 3 study of patisiran in patients with attr amyloidosis with cardiomyopathy at heart failure society of america annual meeting

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced results from exploratory endpoints and additional analyses of prespecified patient subgroups for the primary and secondary endpoints in the apollo-b phase 3 study of patisiran, an investigational rnai therapeutic in development for the treatment of transthyretin-mediated (attr) amyloidosis with cardiomyopathy. the results were presented during a moderated poste
ALNY Ratings Summary
ALNY Quant Ranking